Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kenneth Beer
With
Allergan
Age
18–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Outpatient, female/male subjects of any race, 18-75 years of age.
Subjects of childbearing potential must have a negative urine pregnancy test result at Baseline and practice a reliable method of contraception throughout the study
Patients with hypotrichosis (thinning) of the eyebrows with a GEyA score of 1 or 2.
Patient agrees to abstain from any treatment to the eyebrows including: waxing, plucking, threading, laser hair removal, and/or bleaching (excluding the glabella region).
Able to understand the requirements of the study and sign Informed Consent/HIPAA Authorization forms.
Written informed consent and written authorization for use or release of health and research information obtained.
Willing to complete all required study visits, procedures, and evaluations including photography.
You may not be if
Subjects who are pregnant (positive urine pregnancy test), planning to become pregnant, breast-feeding, or who are of childbearing potential and not practicing a reliable method of birth control.
Patients with any uncontrolled systemic disease
Patient with any known disease or abnormality of the eyebrows including eczema and seborrheic dermatitis
Patients with known or suspected trichotillomania disorder
Patients with a history of glaucoma and/or increased ocular pressure
Patients who are currently using an IOP-lowering prostaglandin analog (including Lumigan)
Patients with a known hypersensitivity to bimatoprost or any other ingredient in Latisse
Previous cosmetic surgery to the upper face (e.g., periorbital surgery, brow lift, eyelid or eyebrow surgery, etc.).
Patients with permanent eye and/or eyebrow make-up
Any eyebrow tint or dye applications within 2 months prior to study entry
Any planned facial cosmetic procedure that would interfere with the evaluation of the eyebrows
Participation in another investigational drug or device study within the last 30 days
Clareo Health | Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo
